Q-omics provides the consensus-scored MIR324 profile across patient tissues and cancer cell-line models. MIR324 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR324 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, MIR324 RNA expression shows 11,798 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where MIR324 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR324 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR324 survival associations across molecular data types. MIR324 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR324 RNA expression–survival associations across cancer types. High MIR324 expression shows unfavorable associations in ACC, PRAD, KIRC and LGG, but favorable associations in BLCA and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR324 RNA expression.
This table summarizes MIR324 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR324. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR324 shows lower tumor expression in BRCA and HNSC and higher tumor expression in KIRC, COAD, CHOL and UCEC. The KIRC box plot shows higher MIR324 RNA expression in tumor versus normal tissue (log2 FC = +0.664, t-test p < 0.001).
This table shows molecular features associated with MIR324 in patient tissues and cancer cell lines. In patient samples, MIR324 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
